NEUROCRINE BIOSCIENCES INC

NBIX Net selling

CIK 0000914475 #761 in the set updated 17 Sep 2026

Bought (120 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$589.89M

$23.99M on a plan · $482.11M straight out of an exercise

Sold at will

$83.79M

323 of 703 sales

Net

−$589.89M

−$83.79M against sales at will

By person

27 insiders · 739 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

GORMAN KEVIN CHARLES

Director

—

$172.84M (56) scheduled

−$172.84M

517,797

0.5094%

$81.40M

−2.8%

Bozigian Haig P.

Chief Development Officer

—

$48.55M (57) scheduled

−$48.55M

157,651

0.1551%

$24.78M

−11.6%

BENEVICH ERIC

Chief Commercial Officer

—

$47.31M (61) scheduled

−$47.31M

67,297

0.0662%

$10.58M

−52.3%

Gano Kyle

Chief Executive Officer

—

$43.53M (61) scheduled

−$43.53M

154,728

0.1522%

$24.32M

−28.0%

Grigoriadis Dimitri E.

Chief Research Officer

—

$43.06M (46) scheduled

−$43.06M

82,273

0.0809%

$12.93M

−56.5%

Lippoldt Darin

Chief Legal Officer

—

$35.52M (78) scheduled

−$35.52M

56,793

0.0559%

$8.93M

−52.9%

ROBERTS EIRY

Chief Medical Officer

—

$21.23M (40) scheduled

−$21.23M

35,640

0.0351%

$5.60M

−63.6%

LYONS GARY A

Director

—

$21.05M (23) scheduled

−$21.05M

122,141

0.1202%

$19.20M

−35.8%

Cooke Julie

Chief Human Resources Officer

—

$20.50M (54) scheduled

−$20.50M

24,025

0.0236%

$3.78M

−67.7%

SHERWIN STEPHEN A

Director

—

$18.51M (13) scheduled

−$18.51M

14,860

0.0146%

$2.34M

−50.5%

Lloyd-Smith Malcolm

Chief Integration Officer

—

$17.75M (45) scheduled

−$17.75M

42,337

0.0417%

$6.66M

−59.6%

Onyia Jude

Chief Scientific Officer

—

$16.15M (15) scheduled

−$16.15M

22,647

0.0223%

$3.56M

−18.5%

OBrien Christopher Flint

Former Chief Medical Officer

—

$15.81M (16) scheduled

−$15.81M

55,946

0.0550%

$8.79M

−47.0%

ABERNETHY MATT

Chief Financial Officer

—

$15.33M (35) scheduled

−$15.33M

42,808

0.0421%

$6.73M

−53.6%

RASTETTER WILLIAM H

Director

—

$13.07M (10) scheduled

−$13.07M

43,678

0.0430%

$6.87M

—

POPS RICHARD F

Director

—

$12.48M (12) scheduled

−$12.48M

37,798

0.0372%

$5.94M

+144.4%

Delaet Ingrid

Chief Regulatory Officer

—

$8.91M (35) scheduled

−$8.91M

18,289

0.0180%

$2.87M

+51.1%

MORROW GEORGE J

Director

—

$7.73M (3) scheduled

−$7.73M

10,386

0.0102%

$1.63M

—

Boyer David W.

Chief Corp. Affairs Officer

—

$6.26M (29) scheduled

−$6.26M

8,722

0.0086%

$1.37M

−81.5%

Norwalk Leslie V

Director

—

$3.22M (7) scheduled

−$3.22M

2,430

0.0024%

$381.99K

—

Nevinny Corinne H

Director

—

$685.53K (2)

−$685.53K

43,283

0.0426%

$6.80M

+69.4%

Coughlin Timothy

Chief Financial Officer

—

$252.40K (4)

−$252.40K

137,961

0.1357%

$21.69M

−4.1%

Sharp Shalini

Director

—

$156.94K (1) scheduled

−$156.94K

4,088

0.0040%

$642.63K

—

MOLLICA JOSEPH A

Director

—

—

—

56,042

0.0551%

$8.81M

+50.0%

Mercier Johanna

Director

—

—

—

6,853

0.0067%

$1.08M

—

POON CHRISTINE A

Director

—

—

—

4,753

0.0047%

$747.16K

—

Keswani Sanjay Chandru

Chief Medical Officer

—

—

—

3,281

0.0032%

$515.77K

—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 646

Amendments (4/A) skipped 16

Filings about a different issuer 2

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 86

Sales straight out of an exercise 294

Sales at will 323

Transactions with no price 0

Shares from compensation/vesting 5,255,245

Sales filed before the plan box existed 321

History held since 2 Sep 2016